Myeloid Leukemia in Remission

Known as: Myelocytic Leukemia in Remission, Myelogenous Leukemia in Remission, Unspecified myeloid leukemia, in remission 
Myeloid leukemia not growing, responding to treatment.
National Institutes of Health

Topic mentions per year

Topic mentions per year

1976-2018
02419762018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Patients with newly diagnosed AML (n = 360) including 137 (38%) with normal karyotype (NK) were evaluated. Overall, 60 (16.6… (More)
  • figure 1
  • table I
  • table II
  • figure 2
  • figure 3
Is this relevant?
2013
2013
PURPOSE Cyclophosphamide (Cy) combined with total-body irradiation (TBI) or with busulfan (Bu) are currently the most common… (More)
Is this relevant?
2011
2011
del(20q) can be observed in hematologic neoplasms, including chronic myelogenous leukemia (CML), and has been reported in… (More)
Is this relevant?
2009
2009
PURPOSE The therapeutic effect of allogeneic hematopoietic stem cell transplantation (HSCT) for patients with myeloid… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Intensive, myelosuppressive therapy is necessary to maximize outcomes for patients with acute myeloid leukemia (AML). A… (More)
Is this relevant?
2000
2000
Intensive, myelosuppressive therapy is necessary to maximize outcomes for patients with acute myeloid leukemia (AML). A… (More)
Is this relevant?
1998
1998
Thirty-eight patients with hematological malignancies, received T cell-depleted marrow transplants (BMT) and cyclosporine to… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
1997
1997
The presence of residual leukemic cells was studied using metaphase-fluorescence in situ hybridization (FISH) in 22 patients with… (More)
  • table 1
  • figure 1
Is this relevant?
1995
1995
CD44 is a widely expressed, multifunctional, cell-surface glycoprotein that has been implicated in the regulation of normal… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
1982
1982
1-beta-D-Arabinofuranosylcytosine (ara-C), 2 or 3 g/sq m, was administered as a 1-hr i.v. infusion every 12 hr for 10 or 12 doses… (More)
Is this relevant?